Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of KNC Laboratories Co., Ltd.. A complete text table follows the diagram.
Pharma generated JPY1.42B of JPY3.37B in revenue, while biotechnology delivery delays and capacity investment pushed operating profit near break-even.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Pharmaceutical business | 1 | 1.4B | 42.0% of reported total |
| Functional materials | 1 | 1.4B | 41.8% of reported total |
| Biotechnology business | 1 | 548M | 16.2% of reported total |
| Revenue | 2 | 3.4B | JPY3.374B six-month life-science manufacturing revenue |
| From | To | Value |
|---|---|---|
| Pharmaceutical business | Revenue | 1.4B |
| Functional materials | Revenue | 1.4B |
| Biotechnology business | Revenue | 548M |